The 148 week data also raised doubt about the S1R variant playing a riole as it did not correlate to a worse response for MMSE performance. For MMSE, only concentration of drug, baseline MMSE and ApoE4 status correlated. Not exactly precision medicine as higher concentration/dose and early disease often correlate to better response with many drugs and disease states. I think it’s slide 17 at the recent CTAD talk. FWIW S1R still correlated to better ADCS-ADL response in the few patients still in the study with high concentration and mild disease — slide 16 I think.
Market Data 
Markets 
AI
